


## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32752A  
APPLICATION NO.  
10/534,572  
APPLICANT  
John Arthur Hohnaker  
FILING DATE  
MAY 11, 2005

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SUS	AM	*WO 01/10859	02/15/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

SUS	AR	Ascoli, Scalzo, Facciolo and Nardi, "Platelet-Derived Growth Factor Receptor Immunoreactivity in Mesothelioma and Nonneoplastic Mesothelial Cells in Serous Effusions", <i>Acta Cytologica</i> , Vol. 39, No. 4, pp. 613-622 (1995).
	AS	Fitzpatrick, Peroni and Bielefeldt-Ohmann, "The Role of Growth Factors and Cytokines in the Tumorigenesis and Immunobiology of Malignant Mesothelioma", <i>Am J Respir Cell Mol</i> , Vol. 12, No. 5, pp. 455-460 (1995).
	AT	Garlepp and Leong, "Biological and Immunological Aspects of Malignant Mesothelioma", <i>Eur Respir J</i> , Vol. 8, No. 4, pp. 643-650 (1995).

EXAMINER

DATE CONSIDERED

3/14/06

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32752A  
APPLICATION NO.  
10/534,572  
APPLICANT  
John Arthur Hohneker  
FILING DATE  
MAY 11, 2005

Group

EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

803	DA	Klominek, Baskin and Hauzenberger, "Platelet-Derived Growth Factor (PDGF) BB Acts as a Chemoattractant for Human Malignant Mesothelioma Cells via PDGF Receptor $\beta$ - Integrin $\alpha 3 \beta 1$ Interaction", <i>Clin Exp Metastasis</i> , Vol. 16, No. 6, pp. 529-539 (1998).
	DB	Langerak et al., "Expression of the Wilms' Tumor Gene <i>WT1</i> in Human Malignant Mesothelioma Cell Lines and Relationship to Platelet-Derived Growth Factor A and Insulin-Like Growth Factor 2 Expression", <i>Genes Chromosomes Cancer</i> , Vol. 12, No. 2, pp. 87-96 (1995).
	DC	Langerak, van der Linden-van Beurden and Versnel, "Regulation of Differential Expression of Platelet-Derived Growth Factor $\alpha$ - and $\beta$ -Receptor mRNA in Normal and Malignant Human Mesothelial Cell Lines", <i>Biochim Biophys Acta</i> , Vol. 1305, Nos. 1-2, pp. 63-70 (1996).
	DD	Langerak et al., "Expression of Platelet-Derived Growth Factor (PDGF) and PDGF Receptors in Human Malignant Mesothelioma <i>in Vitro</i> and <i>in Vivo</i> ", <i>J Pathol</i> , Vol. 178, No. 2, pp. 151-160 (1996).
	DE	*Lin et al., "The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment", <i>Cancer Res</i> , Vol. 62, No. 17, pp. 5019-5026 (2002).
	DF	*Maung, "Novel Drugs in Development for Malignant Mesothelioma", <i>Clin Lung Cancer</i> , Vol. 4, No. 3, pp. 146-148 (2002).
	DG	Metheny-Barlow et al., "Paradoxical Effects of Platelet-Derived Growth Factor-A Overexpression in Malignant Mesothelioma. Antiproliferative Effects <i>In Vitro</i> and Tumorigenic Stimulation <i>In Vivo</i> ", <i>Am J Respir Cell Mol Biol</i> , Vol. 24, No. 6, pp. 694-702 (2001).
	DH	Pogrebniak, Lubensky and Pass, "Differential Expression of Platelet Derived Growth Factor- $\beta$ in Malignant Mesothelioma: A Clue to Future Therapies?", <i>Surg Oncol</i> , Vol. 2, No. 4, pp. 235-240 (1993).
	DI	Ruffié, "New Therapeutic Options for Mesothelioma", <i>Rev Pneumol Clin</i> , Vol. 58, No. 5, Pt. 2, pp. 3S15-3S18 (2002) - English Translation.
	DJ	Syrokou, Tzanakakis, Hjerpe and Karamanos, "Proteoglycans in Human Malignant Mesothelioma. Stimulation of their Synthesis Induced by Epidermal, Insulin and Platelet-Derived Growth Factors Involves Receptors with Tyrosine Kinase Activity", <i>Biochimie</i> , Vol. 81, No. 7, pp. 733-744 (1999).
	DK	Van der Meeren et al., "Tumorigenic Conversion of Human Mesothelial Cells as a Consequence of Platelet-Derived Growth Factor-A Chain Overexpression", <i>Am J Respir Cell Mol Biol</i> , Vol. 8, No. 2, pp. 214-221 (1993).
	DL	Versnel et al., "Human Malignant Mesothelioma Cell Lines Express PDGF $\beta$ -Receptors Whereas Cultured Normal Mesothelial Cells Express Predominantly PDGF $\alpha$ -Receptors", <i>Oncogene</i> , Vol. 6, No. 11, pp. 2005-2011 (1991).
	DM	Zanella, Posada, Tritton and Mossman, "Asbestos Causes Stimulation of the Extracellular Signal-Regulated Kinase 1 Mitogen-Activated Protein Kinase Cascade after Phosphorylation of the Epidermal Growth Factor Receptor", <i>Cancer Res</i> , Vol. 56, No. 23, pp. 5334-5338 (1996).
	DN	

EXAMINER

*Bender*

DATE CONSIDERED

3/14/00

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.